Aires Pharmaceuticals Secures $20,000,000 Series B Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d182a135-8936-4799-ba02-4104c204a4c9&Preview=1 -
Date
11/12/2010 -
Company Name
Aires Pharmaceuticals -
Mailing Address
4690 Executive Drive San Diego, CA 92121 -
Company Description
As a first product opportunity, the Company is developing an inhaled drug that has been demonstrated in animal models to treat both adult and pediatric pulmonary hypertension. As a second product opportunity, Aires is also pursuing indications associated with the treatment of bacterial pulmonary infections. -
Website
http://www.airespharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$20,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Additionally, Aires further bolstered its cash reserves by entering into an agreement with Novartis International Pharmaceutical Limited whereby Novartis has been granted an exclusive option to acquire Aires following the successful completion of a Phase 2 clinical study of Aironite™ to treat pulmonary arterial hypertension. -
M&A Terms
-
Venture Investor
MPM Capital -
Venture Investor
ProQuest Investments
